SCHEMBL10065714

SCHEMBL10065714

CN[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)NCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRSS1 P07477 3/20 0.50
▸ PRSS2 P07478 3/20 0.50
▸ PRSS3 P35030 3/20 0.50
▸ TPSAB1 Q15661 3/20 0.50
▸ F2 P00734 2/20 0.50
▸ PLG P00747 2/20 0.50
▸ CAPN1 P07384 2/20 0.47
▸ PKM P14618 2/20 0.47
▸ FOLH1 Q04609 4/20 0.46
▸ VHL P40337 1/20 0.43
▸ ELOC Q15369 1/20 0.43
▸ ELOB Q15370 1/20 0.43
▸ HSP90AB1 P08238 1/20 0.42
▸ CNR1 P21554 1/20 0.41
▸ L3MBTL3 Q96JM7 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ EGLN1 Q9GZT9 1/20 0.41
▸ KDM2A Q9Y2K7 1/20 0.41
▸ RAMP3 O60896 2/20 0.40
▸ CALCR P30988 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10066226 0.86 CAPN1 (0.58) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL10066201 0.83 PRSS1 (0.49) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL12984158 0.81 CAPN1 (0.56) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL10065813 0.80 PRSS1 (0.47) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL12984633 0.79 APLNR (0.49) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL10066224 0.77 RAMP3 (0.51) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL19229658 0.74 PKM (0.70) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL10215078 0.73 PKM (0.68) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL12985194 0.72 FOLH1 (0.63) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL17171624 0.72 PKM (0.68) PRSS1PRSS2PRSS3TPSAB1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165211-A1 Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques BRACCO IMAGING S.P.A. (IT) 2012-06-28 — — US disclosed
US-20100316563-A1 Method For The Preparation Of New Oligoclonal Antibodies BRACCO IMAGING S.P.A. (IT) 2010-12-16 — — US disclosed
US-20100316563-A1 Method For The Preparation Of New Oligoclonal Antibodies BRACCO IMAGING S.P.A. (IT) 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316563-A1 Method For The Preparation Of New Oligoclonal Antibodies APOB, APOL1, FCGR3B PRSS1 3190/4885PRSS2 2304/4885PRSS3 2581/4885
US-20120165211-A1 Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques TAGLN2, TTN, TXLNA PRSS1 2410/4885PRSS2 2765/4885PRSS3 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback